In addition, another trial (the AZTEC study group) reported that early AZA therapy is more effective for preventing a moderate to severe relapse in a post hoc analysis [ 25].
Surgical resection offers the best chance for cure for early stage non-small-cell lung cancer (NSCLC, stage I, II, IIIA), but the 5-year survival rates are only moderate, with systemic relapse being the major cause of death.
Briefly, in patients with moderate risk for relapse the sequential delivery of CMF followed by adriamycin was compared with CMF alone, whereas in a second study conducted in high-risk patient the inverse sequence (adriamycin followed by CMF) was tested.
At study design, primary end-point was defined as moderate-to-severe relapse at 12 months while secondary end-point was moderate-to-severe relapse at 24 months.
The event was predominantly singular, but four patients had moderate or severe relapses.
There was a significant difference in survival without moderate-to-severe relapse between CD and UC assessed by logrank test (P = 0.035).
The most common therapies for the treatment of moderate and severely relapsing AD are topical corticosteroids, emollients, oral antihistamines, antibiotic agents, immunosuppressive agents, or non-pharmacologic approaches[ 2].
For UC patients, thiopurines were reintroduced in 24 of 34 (71%) patients with a moderate-to-severe relapse not requiring surgery or anti-TNF.
In patients with CD, our study shows a moderate-to-severe relapse rate of 24% at 1 year and 39% at 2 years after thiopurine withdrawal.
23% of CD patients had a moderate-to-severe relapse within 12 months of thiopurine withdrawal as compared to 12% in UC patients.
